PAIN
Volume 139, Issue 3 , Pages 533-540 , 31 October 2008

Profound reduction of somatic and visceral pain in mice by intrathecal administration of the anti-migraine drug, sumatriptan

  • Tetsuro Nikai

      Affiliations

    • Department of Anatomy, University of California San Francisco, San Francisco, CA, USA
    • Department of Anesthesiology, Shimane University, Izumo, Japan
    • ,
  • Allan I. Basbaum

      Affiliations

    • Departments of Anatomy and Physiology, W.M. Keck Foundation Center for Integrative Neuroscience, University of California San Francisco, San Francisco, CA, USA
    • ,
  • Andrew H. Ahn

      Affiliations

    • Departments of Neurology and Anatomy, University of California San Francisco, San Francisco, CA, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 415 476 3557; fax: +1 415 476 1974.

Received 31 July 2007 ,Revised 27 May 2008 ,Accepted 2 June 2008.

References 

  1. Abbadie C, Taylor BK, Peterson MA, Basbaum AI. Differential contribution of the two phases of the formalin test to the pattern of c-fos expression in the rat spinal cord: studies with remifentanil and lidocaine. Pain. 1997;69:101–110
  2. Ahn AH, Basbaum AI. Tissue injury regulates serotonin 1D receptor expression: implications for the control of migraine and inflammatory pain. J Neurosci. 2006;26:8332–8338
  3. Bao L, Jin SX, Zhang C, Wang LH, Xu ZZ, Zhang FX, et al. Activation of delta opioid receptors induces receptor insertion and neuropeptide secretion. Neuron. 2003;37:121–133
  4. Bartsch T, Knight YE, Goadsby PJ. Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception. Ann Neurol. 2004;56:371–381
  5. Basbaum AI. Distinct neurochemical features of acute and persistent pain. Proc Natl Acad Sci USA. 1999;96:7739–7743
  6. Bergstrom M, Yates R, Wall A, Kagedal M, Syvanen S, Langstrom B. Blood–brain barrier penetration of zolmitriptan -- modelling of positron emission tomography data. J Pharmacokinet Pharmacodyn. 2006;33:75–91
  7. Bingham S, Davey PT, Sammons M, Raval P, Overend P, Parsons AA. Inhibition of inflammation-induced thermal hypersensitivity by sumatriptan through activation of 5-HT(1B/1D) receptors. Exp Neurol. 2001;167:65–73
  8. Buzzi MG, Carter WB, Shimizu T, Heath H, Moskowitz MA. Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology. 1991;30:1193–1200
  9. Cahill CM, Morinville A, Hoffert C, O’Donnell D, Beaudet A. Up-regulation and trafficking of delta opioid receptor in a model of chronic inflammation: implications for pain control. Pain. 2003;101:199–208
  10. Cahill CM, Morinville A, Lee MC, Vincent JP, Collier B, Beaudet A. Prolonged morphine treatment targets delta opioid receptors to neuronal plasma membranes and enhances delta-mediated antinociception. J Neurosci. 2001;21:7598–7607
  11. Cao YQ, Mantyh PW, Carlson EJ, Gillespie AM, Epstein CJ, Basbaum AI. Primary afferent tachykinins are required to experience moderate to intense pain. Nature. 1998;392:390–394
  12. Carmichael NM, Charlton MP, Dostrovsky JO. Activation of the 5-HT(1B/D) receptor reduces hindlimb neurogenic inflammation caused by sensory nerve stimulation and capsaicin. Pain. 2008;134:95–105
  13. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 1994;53:55–63
  14. Cheng PY, Svingos AL, Wang H, Clarke CL, Jenab S, Beczkowska IW, et al. Ultrastructural immunolabeling shows prominent presynaptic vesicular localization of δ-opioid receptor within both enkephalin- and nonenkephalin-containing axon terminals in the superficial layers of the rat cervical spinal cord. J Neurosci. 1995;15:5976–5988
  15. Connor HE, Feniuk W, Beattie DT, North PC, Oxford AW, Saynor DA, et al. Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia. 1997;17:145–152
  16. Cumberbatch MJ, Hill RG, Hargreaves RJ. Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol. 1997;328:37–40
  17. Cumberbatch MJ, Hill RG, Hargreaves RJ. Differential effects of the 5HT1B/1D receptor agonist naratriptan on trigeminal versus spinal nociceptive responses. Cephalalgia. 1998;18:659–663
  18. Daher JB, de Melo MD, Tonussi CR. Evidence for a spinal serotonergic control of the peripheral inflammation in the rat. Life Sci. 2005;76:2349–2359
  19. Fairbanks CA. Spinal delivery of analgesics in experimental models of pain and analgesia. Adv Drug Deliv Rev. 2003;55:1007–1041
  20. Ghelardini C, Galeotti N, Nicolodi M, Donaldson S, Sicuteri F, Bartolini A. Involvement of central cholinergic system in antinociception induced by sumatriptan in mouse. Int J Clin Pharmacol Res. 1997;17:105–109
  21. Goadsby PJ, Classey JD. Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience. 2003;122:491–498
  22. Goadsby PJ, Hoskin KL. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine?. Pain. 1996;67:355–359
  23. Hoskin KL, Goadsby PJ. Comparison of more and less lipophilic serotonin (5HT1B/1D) agonists in a model of trigeminovascular nociception in cat. Exp Neurol. 1998;150:45–51
  24. Jain NK, Kulkarni SK. Antinociceptive effect of sumatriptan in mice. Indian J Exp Biol. 1998;36:973–979
  25. Jennings EA, Ryan RM, Christie MJ. Effects of sumatriptan on rat medullary dorsal horn neurons. Pain. 2004;111:30–37
  26. Jeong CY, Choi JI, Yoon MH. Roles of serotonin receptor subtypes for the antinociception of 5-HT in the spinal cord of rats. Eur J Pharmacol. 2004;502:205–211
  27. Johnson DE, Rollema H, Schmidt AW, McHarg AD. Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain. Eur J Pharmacol. 2001;425:203–210
  28. Kaube H, Hoskin KL, Goadsby PJ. Inhibition by sumatriptan of central trigeminal neurones only after blood–brain barrier disruption. Br J Pharmacol. 1993;109:788–792
  29. Kayser V, Aubel B, Hamon M, Bourgoin S. The antimigraine 5-HT(1B/1D) receptor agonists, sumatriptan, zolmitriptan and dihydroergotamine, attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain. Br J Pharmacol. 2002;137:1287–1297
  30. Kayser V, Elfassi IE, Aubel B, Melfort M, Julius D, Gingrich JA, et al. Mechanical, thermal and formalin-induced nociception is differentially altered in 5-HT1A−/−, 5-HT1B−/−, 5-HT2A−/−, 5-HT3A−/− and 5-HTT−/− knock-out male mice. Pain. 2007;130:235–248
  31. Levy D, Jakubowski M, Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc Natl Acad Sci USA. 2004;101:4274–4279
  32. McCarson KE, Goldstein BD. Release of substance P into the superficial dorsal horn following nociceptive activation of the hindpaw of the rat. Brain Res. 1991;568:109–115
  33. McNamara CR, Mandel-Brehm J, Bautista DM, Siemens J, Deranian KL, Zhao M, et al. TRPA1 mediates formalin-induced pain. Proc Natl Acad Sci USA. 2007;104:13525–13530
  34. Nadeson R, Goodchild CS. Antinociceptive role of 5-HT1A receptors in rat spinal cord. Br J Anaesth. 2002;88:679–684
  35. Patwardhan AM, Berg KA, Akopain AN, Jeske NA, Gamper N, Clarke WP, et al. Bradykinin-induced functional competence and trafficking of the delta-opioid receptor in trigeminal nociceptors. J Neurosci. 2005;25:8825–8832
  36. Pitcher GM, Henry JL. Nociceptive response to innocuous mechanical stimulation is mediated via myelinated afferents and NK-1 receptor activation in a rat model of neuropathic pain. Exp Neurol. 2004;186:173–197
  37. Potrebic S, Ahn AH, Skinner K, Fields HL, Basbaum AI. Peptidergic nociceptors of both trigeminal and dorsal root ganglia express serotonin 1D receptors: implications for the selective antimigraine action of triptans. J Neurosci. 2003;23:10988–10997
  38. Shepheard SL, Williamson DJ, Williams J, Hill RG, Hargreaves RJ. Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats. Neuropharmacology. 1995;34:255–261
  39. Shields SD, Eckert WA, Basbaum AI. Spared nerve injury model of neuropathic pain in the mouse: a behavioral and anatomic analysis. J Pain. 2003;4:465–470
  40. Skingle M, Birch PJ, Leighton GE, Humphrey PP. Lack of antinociceptive activity of sumatriptan in rodents. Cephalalgia. 1990;10:207–212
  41. Smith D, Hill RG, Edvinsson L, Longmore J. An immunocytochemical investigation of human trigeminal nucleus caudalis: CGRP, substance P and 5-HT1D-receptor immunoreactivities are expressed by trigeminal sensory fibres. Cephalalgia. 2002;22:424–431
  42. Stewart PE, Hammond DL. Activation of spinal delta-1 or delta-2 opioid receptors reduces carrageenan-induced hyperalgesia in the rat. J Pharmacol Exp Ther. 1994;268:701–708
  43. Tjolsen A, Berge OG, Hunskaar S, Rosland JH, Hole K. The formalin test: an evaluation of the method. Pain. 1992;51:5–17
  44. Wotherspoon G, Priestley JV. Expression of the 5-HT1B receptor by subtypes of rat trigeminal ganglion cells. Neuroscience. 2000;95:465–471

PII: S0304-3959(08)00300-X

doi: 10.1016/j.pain.2008.06.002

PAIN
Volume 139, Issue 3 , Pages 533-540 , 31 October 2008

Article Tools

* Image Usage & Resolution